Baseline characteristics and demographic data of patients from SWEFOT trial
| Baseline characteristics, mean (±SD) | All patients (n=487)* | Subset of patients with clinical measures at baseline and radiographs at baseline and 1 year | p Value | ||
|---|---|---|---|---|---|
| Radiographic subset (n=235) | Without progression (ΔSHS≤5) (n=192) | With progression (ΔSHS>5) (n=43) | |||
| Female, N (%) | 344 (70) | 169 (72) | 137 (71) | 32 (74) | 0.686 |
| Symptom duration (months) | 6.2 (4.57) | 6.1 (5.1) | 6.0 (5.38) | 6.6 (3.61) | 0.502 |
| Anti-CCP status, N (%) | 0.075 | ||||
| Positive | 275 (57) | 133 (57) | 103 (53) | 30 (70) | |
| Negative | 157 (32) | 92 (39) | 80 (42) | 12 (28) | |
| Not available | 55 (11) | 10 (4) | 9 (5) | 1 (2) | |
| RF status, N (%) | 0.094 | ||||
| Positive | 330 (68) | 153 (65) | 120 (63) | 33 (77) | |
| Negative | 152 (31) | 80 (34) | 70 (36) | 10 (23) | |
| Not available | 5 (1) | 2 (1) | 2 (1) | 0 (0) | |
| 28 swollen joint count | 10.8 (5.28) | 10.8 (5.31) | 10.7 (5.30) | 11.0 (5.43) | 0.807 |
| 28 tender joint count | 9.6 (6.07) | 9.3 (5.86) | 9.4 (5.99) | 8.77 (5.25) | 0.518 |
| ESR (mm/h) | 39.9 (25.9) | 41.3 (26.9) | 38.5 (24.46) | 53.9 (33.52) | 0.001 |
| CRP level (mg/L) | 33.8 (36.81) | 35.4 (38.37) | 32.5 (36.41) | 48.3 (44.31) | 0.018 |
| Patient's global assessment of disease activity (VAS 0–100 mm) score | 56 (23.9) | 55.4 (24.67) | 54.1 (24.96) | 61.3 (22.70) | 0.082 |
| DAS28 | 5.7 (1.01) | 5.7 (1.02) | 5.7 (1.00) | 5.9 (1.14) | 0.107 |
| DAS28-CRP | 6.5 (1.22) | 5.4 (0.99) | 5.3 (0.97) | 5.5 (1.04) | 0.237 |
| MBDA score | 58.6 (15.08) | 59.6 (14.71) | 57.9 (14.68) | 67.2 (12.38) | <0.001 |
| SHS mean (median) | 4.5 (2) | 4.7 (2) | 4.3 (1) | 6.5 (3) | 0.126 |
*For “All patients” column the number of missing patients: 28 swollen and tender joint count (n=2), ESR (n=5), CRP and patient's global assessment (n=3), DAS28 and DAS28-ESR (n=8), MBDA (n=185) and SHS (n=57).
anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; MBDA, multi-biomarker disease activity; RF, rheumatoid factor; SHS, Sharp–van der Heijde score; VAS, visual analogue scale.